SHS_543136 REPP CPHS 17161

Evaluating the Efficacy and Safety of Transitioning Patients from Natalizumab to Ocrelizumab (OCTAVE)

Phase IV
NCT03157830
Neurosciences
Multiple Sclerosis
Pavle Repovic, M.D.
Genentech
Yuriko Courtney
  • Providence Health Care
  • Swedish Medical Center